AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15332782 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation with antirabies vaccine
Number of subjects: 40
Study 15332782 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only the antirabies vaccine
Number of subjects: 40
Study 9241094 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone: beta-cyclodextrin complex (SP-COMP)
Number of subjects: 13
Study 9241094 — intervention group
Group type: COMPARATOR
Intervention: Aldactone tablets (ALD)
Number of subjects: 13
Study 8302149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam 0.05 mg/kg, meperidine 1 mg/kg, and buscopan 20 mg (Group IV‐MMB)
Number of subjects: 299
Study 8302149 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular meperidine 50 mg and buscopan 20 mg (Group IM‐MB)
Number of subjects: 299
Study 8302149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 299
Study 3127114 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of combination oral contraceptive tablet (250 micrograms LNG and 50 micrograms EE2)
Number of subjects: 5
Study 3127114 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of combination oral contraceptive tablet (250 micrograms LNG and 50 micrograms EE2)
Number of subjects: 5
Study 3127114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of combination oral contraceptive tablet (250 micrograms LNG and 50 micrograms EE2)
Number of subjects: 5
Study 31665873 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF: 6 mg/kg body mass)
Number of subjects: 9
Study 31665873 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study 31665873 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 9
Study 29091512 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop Vertical Jump (DVJ)
Number of subjects: 60
Study 29091512 — intervention group
Group type: COMPARATOR
Intervention: Step-Down Test (SDT)
Number of subjects: 60
Study 29157276 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Surgical Periodontal Therapy (NSPT)
Number of subjects: 66
Study 29157276 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 66
Study 25721919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 30
Study 25721919 — intervention group
Group type: COMPARATOR
Intervention: Conventional suturing
Number of subjects: 30
Study 23219296 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 15056
Study 23219296 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg and simvastatin 20 to 40 mg
Number of subjects: 15056
Study 23219296 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose statin therapy (Atorvastatin 10 mg and simvastatin 20 to 40 mg)
Number of subjects: 15056
Study 22286630 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium excision with complete suture of conjunctiva (PESC)
Number of subjects: 120
Study 22286630 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium excision with conjunctival auto‐graft transplantation with graft from the inferior temporal bulbar conjunctiva (ITBC)
Number of subjects: 120
Study 22286630 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium excision with conjunctival auto‐graft transplantation with graft from the superior temporal bulbar conjunctiva (STBC)
Number of subjects: 120
Study 19359622 — intervention group
Group type: EXPERIMENTAL
Intervention: EMS intervention with strategic placement of stroke education media
Number of subjects: 5
Study 19359622 — intervention group
Group type: COMPARATOR
Intervention: Control counties with no EMS intervention
Number of subjects: 5
Study 15976922 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Network Test - Executive Attention
Number of subjects: 41
Study 15976922 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Network Test - Effortful Control
Number of subjects: 41
Study 15976922 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Network Test - Negative Affectivity
Number of subjects: 41
Study 15976922 — intervention group
Group type: COMPARATOR
Intervention: Attention Network Test - Alerting and Orienting
Number of subjects: 41
Study 14690100 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon's bupivacaine (4-5 mL of bupivacaine 0.75%)
Number of subjects: 43
Study 14690100 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 43
Study 11109391 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational units
Number of subjects: 4
Study 11109391 — intervention group
Group type: COMPARATOR
Intervention: Ordinary hospital units
Number of subjects: 4
Study 8603458 — intervention group
Group type: EXPERIMENTAL
Intervention: Early prophylaxis group (rhG‐CSF initiated on day 2)
Number of subjects: 33
Study 8603458 — intervention group
Group type: EXPERIMENTAL
Intervention: Late prophylaxis group (rhG‐CSF initiated on day 8)
Number of subjects: 33
Study 8603458 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic group (rhG‐CSF initiated after onset of neutropenia)
Number of subjects: 33
Study 8603458 — intervention group
Group type: COMPARATOR
Intervention: No-support group (MVP therapy without rhG‐CSF)
Number of subjects: 33
Study 16967580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (5 mg/kg body weight over 30 min)
Number of subjects: 0
Study 16967580 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study 3840565 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30
Study 3840565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29587863 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenzhuo Formula (SZF)
Number of subjects: 120
Study 29587863 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 120
Study 27686945 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy (3 cycles of intravenous docetaxel 60 mg/m2 on day 1, intravenous cisplatin 60 mg/m2 on day 1, continuous intravenous fluorouracil 600 mg/m2 per day from day 1 to day 5 every 3 weeks)
Number of subjects: 480
Study 27686945 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy alone (3 cycles of 100 mg/m2 cisplatin every 3 weeks with intensity-modulated radiotherapy)
Number of subjects: 480
Study 27686945 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy
Number of subjects: 480
Study 27686945 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy alone
Number of subjects: 480
Study 25068290 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 18
Study 23063367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Number of subjects: 0
Study 23063367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 20205486 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15-60 mg once daily for up to 30 days (n = 95 in SALT-1, n = 118 in SALT-2)
Number of subjects: 536
Study 20205486 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan in a subgroup of 323 patients with hyponatraemia (serum sodium <134 mmol/L) in the EVEREST trials
Number of subjects: 536
Study 20205486 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 89 in SALT-1, n = 114 in SALT-2)
Number of subjects: 536
Study 18204388 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural corticosteroids
Number of subjects: 31
Study 18204388 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 31
Study 18204388 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical techniques
Number of subjects: 31
Study 18204388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical foramenal or epidural injections
Number of subjects: 31
Study 18204388 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical procedures on the cervical spine
Number of subjects: 31
Study 18204388 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative measures
Number of subjects: 31
Study 16126056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 100
Study 16126056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12114414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivaloyloxymethyl butyrate (AN‐9) administered as a 6‐h i.v. infusion daily for 5 days every 3 weeks at dosages ranging from 0.047 to 3.3 g/m2/day.
Number of subjects: 28
Study 12114414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivaloyloxymethyl butyrate (AN‐9) at maximum deliverable dose of 3.3 g/m2/day.
Number of subjects: 28
Study 12114414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivaloyloxymethyl butyrate (AN‐9) treatment.
Number of subjects: 28
Study 12148423 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA group)
Number of subjects: 148
Study 9503298 — intervention group
Group type: EXPERIMENTAL
Intervention: PSSWWG liner worn over an inner latex glove
Number of subjects: 50
Study 9503298 — intervention group
Group type: COMPARATOR
Intervention: Double latex gloves
Number of subjects: 50
Study 8061266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (5 mg)
Number of subjects: 50
Study 8061266 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study 3293527 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized ribavirin
Number of subjects: 0
Study 3293527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31983585 — intervention group
Group type: EXPERIMENTAL
Intervention: Human rotavirus vaccine (HRV), Rotarix, administered over a three-year period.
Number of subjects: 10917
Study 31983585 — intervention group
Group type: COMPARATOR
Intervention: Non-HRV villages (control group).
Number of subjects: 10917
Study 31983585 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV villages.
Number of subjects: 10917
Study 31983585 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV villages with literate mothers.
Number of subjects: 10917
Study 31983585 — intervention group
Group type: COMPARATOR
Intervention: Non-HRV villages.
Number of subjects: 10917
Study 31983585 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV villages with higher phone users.
Number of subjects: 10917
Study 30985861 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect patient care
Number of subjects: 80
Study 30985861 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct patient care
Number of subjects: 80
Study 30985861 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 80
Study 30985861 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitasking with indirect patient care activities
Number of subjects: 80
Study 29093068 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 1,000 U
Number of subjects: 381
Study 29093068 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 1,500 U
Number of subjects: 381
Study 29093068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 29093068 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label cycles (1,000 U, 1,500 U)
Number of subjects: 381
Study 25736977 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted tobacco intervention tool
Number of subjects: 1
Study 25736977 — intervention group
Group type: COMPARATOR
Intervention: Control (non-intervention clinic)
Number of subjects: 1
Study 22730906 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg paracetamol
Number of subjects: 229
Study 22730906 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg etodolac
Number of subjects: 229
Study 22730906 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg etodolac
Number of subjects: 229
Study 21631623 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal models (mixed-effects and generalized estimating equations)
Number of subjects: 0
Study 21631623 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE)
Number of subjects: 0
Study 21631623 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal models
Number of subjects: 0
Study 21631623 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous day's smoking status and recent smoking history
Number of subjects: 0
Study 18440325 — intervention group
Group type: COMPARATOR
Intervention: Renin angiotensin system blockade (RAS blockade)
Number of subjects: 45758
Study 18473977 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in clinical trials
Number of subjects: 0
Study 18473977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric trial design
Number of subjects: 0
Study 18473977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical issues in trials
Number of subjects: 0
Study 18473977 — intervention group
Group type: EXPERIMENTAL
Intervention: Legal situation in clinical trials
Number of subjects: 0
Study 12674390 — intervention group
Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 120
Study 12674390 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 11103193 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA ropivacaine 0.1%, bolus 5 mg, lock-out 15 min, 3 mg h-1 background infusion (group R)
Number of subjects: 47
Study 11103193 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA 0.1% ropivacaine/fentanyl 2 micrograms ml-1 at identical settings (group RF)
Number of subjects: 47
Study 11103193 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA 0.1% ropivacaine/fentanyl (group RF)
Number of subjects: 47
Study 11103193 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA 0.1% ropivacaine (group R)
Number of subjects: 47
Study 8814420 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative REM sleep EEG
Number of subjects: 9
Study 8814420 — intervention group
Group type: COMPARATOR
Intervention: SPECT measures
Number of subjects: 9
Study 8814420 — intervention group
Group type: EXPERIMENTAL
Intervention: Degrees of interhemispheric asymmetry
Number of subjects: 9
Study 14621842 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-61443 (morpholinoethyl ester of mycophenolic acid)
Number of subjects: 0
Study 30939410 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800 mg qAM
Number of subjects: 23
Study 30939410 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) 400 mg BID
Number of subjects: 23
Study 30939410 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 23
Study 30939410 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 23
Study 28597333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pastor support and engagement in promoting the intervention
Number of subjects: 0
Study 28597333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pastor engagement in promoting the program
Number of subjects: 0
Study 28597333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pastor attendance at workshops
Number of subjects: 0
Study 27136316 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural hand tremor measured by quartile (dot method)
Number of subjects: 715
Study 27136316 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural hand tremor measured by quartile (circular method)
Number of subjects: 715
Study 27136316 — intervention group
Group type: COMPARATOR
Intervention: Postural hand tremor
Number of subjects: 715
Study 24766756 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention combined with acamprosate and/or naltrexone
Number of subjects: 1156
Study 22476809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + 5‐fluorouracil + radiotherapy (PF group)
Number of subjects: 90
Study 22476809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + docetaxel + radiotherapy (DP group)
Number of subjects: 90
Study 20510947 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music during the procedure)
Number of subjects: 100
Study 20510947 — intervention group
Group type: COMPARATOR
Intervention: No music therapy (control group)
Number of subjects: 100
Study 17699546 — intervention group
Group type: COMPARATOR
Intervention: Advice and exercise
Number of subjects: 352
Study 17699546 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and exercise plus true acupuncture
Number of subjects: 352
Study 17699546 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and exercise plus non‐penetrating acupuncture
Number of subjects: 352
Study 16198805 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole powder 2% biweekly
Number of subjects: 48
Study 16198805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12030956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous H2-receptor antagonists
Number of subjects: 0
Study 9917121 — intervention group
Group type: EXPERIMENTAL
Intervention: Aplisol
Number of subjects: 1555
Study 9917121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubersol
Number of subjects: 1555
Study 9917121 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-S1
Number of subjects: 1555
Study 9917121 — intervention group
Group type: COMPARATOR
Intervention: PPD-S2
Number of subjects: 1555
Study 8538091 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 micrograms/day of BDP
Number of subjects: 39
Study 8538091 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 micrograms/day of BDP
Number of subjects: 39
Study 8538091 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilators only (Control)
Number of subjects: 39
Study 2188335 — intervention group
Group type: EXPERIMENTAL
Intervention: AGD (aluminium‐adsorbed allergoid) injections
Number of subjects: 36
Study 2188335 — intervention group
Group type: COMPARATOR
Intervention: TA (tyrosine‐adsorbed allergoid) injections
Number of subjects: 36
Study 6268298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 500 mg intramuscularly every eight hours
Number of subjects: 0
Study 6268298 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin 1,000 mg intramuscularly every eight hours
Number of subjects: 0
Study 31500986 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty (RSA)
Number of subjects: 59
Study 31500986 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 59
Study 28641416 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenocyanate (SeCN‐) as a vibrational probe in ultrafast IR experiments
Number of subjects: 0
Study 28638206 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) on the left prefrontal dorsolateral cortex (DLPFC)
Number of subjects: 37
Study 28638206 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 37
Study 24557349 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum EPA
Number of subjects: 290
Study 24557349 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCM EPA
Number of subjects: 290
Study 24557349 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCM EPA+DHA
Number of subjects: 290
Study 24557349 — intervention group
Group type: COMPARATOR
Intervention: Dietary oily fish and seafood intake
Number of subjects: 290
Study 22638798 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg every 2 weeks), Everolimus (5 mg three times weekly), Panitumumab (4.8 mg/kg)
Number of subjects: 32
Study 22638798 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg daily)
Number of subjects: 32
Study 22638798 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (5 mg daily)
Number of subjects: 32
Study 22638798 — intervention group
Group type: EXPERIMENTAL
Intervention: Common adverse events
Number of subjects: 32
Study 19400894 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 2739
Study 19400894 — intervention group
Group type: COMPARATOR
Intervention: Parental-reported IgE-mediated food allergy
Number of subjects: 2739
Study 19400894 — intervention group
Group type: COMPARATOR
Intervention: Sensitization to food allergens
Number of subjects: 2739
Study 19400894 — intervention group
Group type: COMPARATOR
Intervention: Odds ratio comparison between reported and confirmed IgE-mediated food allergy
Number of subjects: 2739
Study 17938126 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS MR stent
Number of subjects: 446
Study 15206657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine CR (100-300 mg/d)
Number of subjects: 279
Study 15206657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 11467241 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 95
Study 11467241 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 95
Study 11467241 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol and Theophylline
Number of subjects: 95
Study 9571327 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg once nightly for 8 weeks, 20 mg for the next 8 weeks, and 40 mg for the third 8-week period)
Number of subjects: 96
Study 9571327 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily throughout the 24 weeks)
Number of subjects: 96
Study 7849231 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg R(‐)‐ibuprofen
Number of subjects: 12
Study 7849231 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg S(+)‐ibuprofen
Number of subjects: 12
Study 7849231 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg R(‐)(‐)+300 mg S(+)‐ibuprofen
Number of subjects: 12
Study 7849231 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg R(‐)(‐)+600 mg S(+)‐ibuprofen
Number of subjects: 12
Study 7849231 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 12
Study 2468859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg b.i.d.)
Number of subjects: 30
Study 2468859 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50 mg b.i.d.)
Number of subjects: 30
Study 2468859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg q.d.) + Captopril (25 mg b.i.d.)
Number of subjects: 30
Study 31574881 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FNB)
Number of subjects: 0